Drug Profile
Research programme: anti-cancer immunotherapies - University College London/Tusk Therapeutics/Cancer Research Technology
Alternative Names: CD25Latest Information Update: 28 Oct 2022
Price :
$50
*
At a glance
- Originator University College London
- Developer Cancer Research Technology; Tusk Therapeutics; University College London
- Class Antibodies; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; Immunosuppressants; Regulatory T lymphocyte inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer